AU771836B2 - Aglyco products and methods of use - Google Patents

Aglyco products and methods of use Download PDF

Info

Publication number
AU771836B2
AU771836B2 AU56986/99A AU5698699A AU771836B2 AU 771836 B2 AU771836 B2 AU 771836B2 AU 56986/99 A AU56986/99 A AU 56986/99A AU 5698699 A AU5698699 A AU 5698699A AU 771836 B2 AU771836 B2 AU 771836B2
Authority
AU
Australia
Prior art keywords
peptide
seq
antibody
aglyco
pipette
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU56986/99A
Other languages
English (en)
Other versions
AU5698699A (en
Inventor
Elenore S. Bogoch
Samuel Bogoch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU5698699A publication Critical patent/AU5698699A/en
Application granted granted Critical
Publication of AU771836B2 publication Critical patent/AU771836B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Jellies, Jams, And Syrups (AREA)
AU56986/99A 1998-09-04 1999-08-30 Aglyco products and methods of use Ceased AU771836B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/146755 1998-09-04
US09/146,755 US6242578B1 (en) 1994-02-17 1998-09-04 Aglyco products and methods of use
PCT/US1999/019836 WO2000018351A2 (en) 1998-09-04 1999-08-30 Aglyco products and methods of use

Publications (2)

Publication Number Publication Date
AU5698699A AU5698699A (en) 2000-04-17
AU771836B2 true AU771836B2 (en) 2004-04-01

Family

ID=22518867

Family Applications (1)

Application Number Title Priority Date Filing Date
AU56986/99A Ceased AU771836B2 (en) 1998-09-04 1999-08-30 Aglyco products and methods of use

Country Status (13)

Country Link
US (4) US6242578B1 (enExample)
EP (2) EP1990058A1 (enExample)
JP (2) JP2004515202A (enExample)
KR (1) KR100451446B1 (enExample)
CN (2) CN101096382A (enExample)
AT (1) ATE406175T1 (enExample)
AU (1) AU771836B2 (enExample)
BR (1) BR9913446A (enExample)
CA (1) CA2341763C (enExample)
DE (1) DE69939430D1 (enExample)
IL (3) IL141775A0 (enExample)
NZ (4) NZ533511A (enExample)
WO (1) WO2000018351A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176275B2 (en) * 1998-09-04 2007-02-13 Samuel Bogoch Anthrax and small pox replikins and methods of use
DE10034712A1 (de) * 2000-07-17 2002-02-07 Arimedes Biotechnology Gmbh Verbrückte Glykokonjugate
US7189800B2 (en) 2001-03-27 2007-03-13 Samuel Bogoch Replikin peptides in rapid replication of glioma cells and in influenza epidemics
US7420028B2 (en) * 2001-03-27 2008-09-02 Samuel Bogoch Replikins and methods of identifying replikin-containing sequences
US7452963B2 (en) * 2001-03-27 2008-11-18 Samuel Bogoch Replikin peptides and antibodies therefore
US7894999B2 (en) 2001-03-27 2011-02-22 Samuel Bogoch Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
JP2004535171A (ja) 2001-03-27 2004-11-25 ボゴーク，サミュエル レプリキンペプチドおよびその使用
US7774144B2 (en) * 2001-10-26 2010-08-10 Samuel Bogoch System and method for identifying complex patterns of amino acids
US7442761B2 (en) 2003-06-06 2008-10-28 Samuel Bogoch Replikin peptides and uses thereof
NZ592340A (en) * 2001-03-27 2012-12-21 Elenore S Bogoch A method for making a virus vaccine compising Replikin peptides
WO2003005880A2 (en) 2001-07-09 2003-01-23 Samuel Bogoch Replikin peptides and uses thereof
KR101067654B1 (ko) * 2001-07-09 2011-09-26 엘레노어 에스 보고치 레플리킨 펩타이드 및 그의 이용
US7306919B1 (en) 2001-10-31 2007-12-11 Thornthwaite Jerry T Antigen-antibody cancer recognition system
US8603345B2 (en) * 2003-02-13 2013-12-10 Becton, Dickinson And Company Devices for component removal during blood collection, and uses thereof
US8494781B2 (en) 2003-06-06 2013-07-23 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
US9254315B2 (en) 2004-04-28 2016-02-09 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
US9002652B1 (en) * 2005-01-27 2015-04-07 Institute For Systems Biology Methods for identifying and using organ-specific proteins in blood
WO2006088962A2 (en) 2005-02-16 2006-08-24 Samuel Bogoch Replikin peptides and uses thereof
US9820986B2 (en) * 2005-03-04 2017-11-21 Taiwan Hopaz Chems, Mfg. Co., Ltd. Glycopeptide compositions
JP2006288670A (ja) * 2005-04-11 2006-10-26 Terumo Corp カテーテル
EP2092059A4 (en) * 2006-10-24 2012-03-28 Bogoch Samuel METHOD FOR FORECASTING INFLUENZA EXCESSIONS BY CORRELATION OF AN INCREASED REPLICINE MIRROR IN WHITE SPOT AND / OR TAURA VIRUSES IN CRABES
US20090017052A1 (en) * 2007-01-18 2009-01-15 Samuel Bogoch Methods of determining lethality of pathogens and malignancies involving replikin peak genes
US20100105634A1 (en) * 2007-03-07 2010-04-29 Cargill, Incorporated Use of glucosamine as a mental and physical stress recovery enhancer and a performance enhancer
MX2009013091A (es) * 2007-05-30 2010-07-30 Bogoch Samuel Peptidos de repliquina sinteticos contra infeccion patogenica de invertebrados en acuicultura.
US20090269367A1 (en) * 2008-04-23 2009-10-29 Samuel Bogoch Methods and compounds for mitigating pathogenic outbreaks using replikin count cycles
US20100144589A1 (en) * 2008-08-08 2010-06-10 Samuel Bogoch Methods of predicting cancer lethality using replikin counts
US9233148B2 (en) 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
CA2842345A1 (en) 2011-07-20 2013-01-24 Samuel Bogoch Peptides shared among lethal cancers and therapeutic compositions comprising said peptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4298590A (en) * 1975-02-25 1981-11-03 Samuel Bogoch Detection of malignant tumor cells
US4840915A (en) * 1975-02-25 1989-06-20 Brain Research, Inc. Method for diagnosing malignant tumors
US4041146A (en) * 1975-05-01 1977-08-09 General Electric Company Method for detection of biological particles
US4486538A (en) * 1978-07-07 1984-12-04 Samuel Bogoch Detection of malignant tumor cells
US5280113A (en) 1989-08-16 1994-01-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
GB9202219D0 (en) 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
AU2289195A (en) * 1995-04-11 1996-10-30 Elenore S. Bogoch Aglyco products

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOGACH S ET AL. CANCER DETECTION & PREVENTION 1988,12,313-20 *

Also Published As

Publication number Publication date
AU5698699A (en) 2000-04-17
CA2341763A1 (en) 2000-04-06
EP1990058A1 (en) 2008-11-12
CN1324258A (zh) 2001-11-28
KR20010072517A (ko) 2001-07-31
NZ544362A (en) 2008-05-30
US6638505B2 (en) 2003-10-28
IL192679A0 (en) 2009-02-11
US20040077532A1 (en) 2004-04-22
ATE406175T1 (de) 2008-09-15
CA2341763C (en) 2014-01-21
DE69939430D1 (de) 2008-10-09
WO2000018351A3 (en) 2000-07-13
BR9913446A (pt) 2004-03-02
IL192679A (en) 2011-10-31
EP1115418A4 (en) 2004-06-09
US20030023047A1 (en) 2003-01-30
IL141775A (en) 2008-11-26
CN1328286C (zh) 2007-07-25
WO2000018351A2 (en) 2000-04-06
US20080241859A1 (en) 2008-10-02
NZ556151A (en) 2009-03-31
JP2011087589A (ja) 2011-05-06
KR100451446B1 (ko) 2004-10-06
CN101096382A (zh) 2008-01-02
NZ533511A (en) 2006-08-31
US7381411B2 (en) 2008-06-03
EP1115418A2 (en) 2001-07-18
EP1115418B1 (en) 2008-08-27
NZ510921A (en) 2004-09-24
US6242578B1 (en) 2001-06-05
IL141775A0 (en) 2002-03-10
JP2004515202A (ja) 2004-05-27

Similar Documents

Publication Publication Date Title
CA2341763C (en) Antigenic peptides of aglyco 10b and antibodies thereto
EP1092027B1 (en) Therapeutic and diagnostic domain 1 beta 2 gp1 polypeptides and methods of using same
Ratnoff et al. Complement as a mediator of inflammation: enhancement of vascular permeability by purified human C'1 esterase
JP2004515202A5 (enExample)
WO2021233885A1 (en) Mimotope peptides of the spike protein from the sars-cov-2 virus
US4174385A (en) Method of identification of surface proteins of cancer cells, clinical test and method of immunization
EP0812191B1 (en) Peptides for the treatment of cancer
KR20000010561A (ko) 항원 특이적 면역억제 요법에 사용하기에 적합한 신규 펩티드
JP2710645B2 (ja) ｓｎＲＮＰ−Ａ抗原及びそのフラグメント
RU2163243C2 (ru) Белки из печени козы, обладающие противоопухолевой активностью, фармацевтическая композиция
Samor et al. Preliminary results on the carbohydrate moiety of factor VIII/von Willebrand factor (FVIII/vWf)
WO2007031100A1 (en) Active immunotherapy of life-threatening systemic inflammation
EP0972032A2 (en) Peptides for the treatment of systemic lupus erythematosus
CH694905A5 (it) Peptidi derivati dalla proteina HMGB1 per l'immunoterapia attiva nell'infiammazione sistematica letale.
TW202535910A (zh) 肽及其用於治療及/或預防多發性硬化症之用途
Gmiński et al. Suceinyl trialanine p-nitroanilide hydrolytic activities in plasma and the aorta of rabbits experimentally immunized with soluble elastin
Rosenthal et al. Chylgastrone: gastric secretory inhibitor in thoracic duct lymph of man and dog
HK1009457A1 (en) Compositions and methods for detecting and treating acquired immunodeficiency syndrome
HK1009457B (en) Compositions and methods for detecting and treating acquired immunodeficiency syndrome

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)